Cutting-edge Wound Care Systems to Aid injured Ukrainians – Thanks to RedDress, a Florida-based Medical Company

RedDress, a Florida-based Israeli medical company is shipping revolutionary blood-clotting wound care systems to Ukraine to help with serious injuries and severe trauma wounds, RedDress announced in a press release Wednesday.

RedDress began shipments of 400 of their ActiGraft systems this week to multiple hospitals in Ukraine to help treat civilian casualties as a result of the indiscriminate Russian attacks.

[mks_pullquote align=”left” width=”300″ size=”24″ bg_color=”#1e73be” txt_color=”#ffffff”]“We’re grateful we’re in a position to not only have a cutting-edge product that has a far greater success rate than traditional wound care treatment options, but also that we have the ability to be financially capable to donate these resources to help so many people in need,”[/mks_pullquote]

In addition to donating the FDA-cleared wound care product, RedDress is coordinating with their partner medical specialists from GraftIn and SlavaMed to help with delivery into Ukraine, while another partner, Dr. Arkadiy Savchenko, a leading expert and Department Surgery No. 2 of Danylo Halytsky Lviv National Medical University, will lead the charge to teach Ukrainian nurses, doctors and aid workers, on how to use the systems.

“We’re grateful we’re in a position to not only have a cutting-edge product that has a far greater success rate than traditional wound care treatment options, but also that we have the ability to be financially capable to donate these resources to help so many people in need,” said Robert Mueller, general manager of RedDress.

According to RedDress, this is the first time their technology will be deployed and used in a war zone. However, their experts believe it will not be the last.

ActiGraft is a new, proprietary and patented technology solution used to help with wound care that enables health care providers to produce – in real time – in vitro blood clots from a patient’s whole blood. Once applied, the blood clot supports wound management and naturally occurring processes in the patient’s body.

While still considered new technology, ActiGraft is quickly becoming a preferred treatment option, especially by doctors who treat complex wounds like those often seen in amputations, post-surgical patients, diabetic patients, vascularly compromised patients, and patients suffering from chronic and traumatic wounds. Showcasing the broad use, just last year, RedDress’s ActiGraft was recognized as one of the year’s Top 10 Innovations by Podiatry Today, a medical trade journal.

The systems are expected to be delivered to Ukraine this week and could be used in the field as early as next week.

RedDress is a privately held, Israel-based company with a U.S. subsidiary, RedDress Ltd., located in Ponte Vedra Beach, Florida. Founded in 2009 with the goal of developing more effective, natural, and economically viable treatments for chronic wounds, RedDress is committed to improving the health and lives of patients around the world with its latest innovation – ActiGraft.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy